Search

LeWitt, PA, RA Hauser, R Pahwa, SH Isaacson, HH Fernandez, M Lew, M Saint-Hilaire, et al. 2019. “Safety and Efficacy of CVT-301 (levodopa Inhalation Powder) on Motor Function During off Periods in Patients With Parkinson’s Disease: A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial. Lancet Neurol 2019;18:145-154.”. Lancet Neurol.

Hauser, RA, SH Isaacson, A Ellenbogen, BE Safirstein, DD Truong, SF Komjathy, DM Kegler-Ebo, P Zhao, and C Oh. 2019. “Orally Inhaled Levodopa (CVT-301) for Early Morning OFF Periods in Parkinson’s Disease. Parkinsonism Relat Disord 2019;64:175-180.”. Parkinsonism Relat Disord.

Hauser, RA, DE Kremens, LW Elmer, DL Kreitzman, RR Walsh, R Johnson, R Howard, JT Nguyen, and R Patni. 2019. “Prevalence of Dyskinesia and OFF by 30-Minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocovri Pivotal Trials. J Parkinsons Dis 2019;9:591-600.”. J Parkinsons Dis.

Vollstedt, EJ, M Kasten, C Klein, and MJFF Global Genetic Parkinson’s Disease Study Group. 2019. “Using Global Team Science to Identify Genetic Parkinson’s Disease Worldwide. Ann Neurol 2019;86:153-157.”. Ann Neurol.

Hermanowicz, N, SA Jones, and RA Hauser. 2019. “Impact of Non-Motor Symptoms in Parkinson’s Disease: A PMDAlliance Survey. Neuropsychiatr Dis Treat 2019;15:2205-2212.”. Neuropsychiatry Dis Treat.

“Frei K, Truong DD, Fahn S, Jankovic J, Hauser RA. The Nosology of Tardive Syndromes. J Neurol Sci 2018;389:10-16.”. 2018. J Neurol Sci.

Bajaj, N, RA Hauser, and ID Grachev. 2013. “Clinical Utility of Dopamine Transporter Single Photon Emission CT (DaT-SPECT) With (123I) Ioflupane in Diagnosis of Parkinsonian Syndromes. J Neurol Neurosurg Psychiatry 2013;84:1288-95.”. J Neurol Neurosurg Psychiatry.

Hauser, RA, and DG Grosset. 2012. “[123I]FP-CIT (DaTscan) SPECT Brain Imaging in Patients With Suspected Parkinsonian Syndromes. J Neuroimaging 2012;22:225-30.”. J Neuroimaging.

Hauser, RA, KE Lyons, and R Pahwa. 2012. “The UPDRS-8: A Brief Clinical Assessment Scale for Parkinson’s Disease. Int J Neurosci 2012;122:333-7.”. Int J Neurosci.

Tetrud, J, P Nausieda, D Kreitzman, GS Liang, A Nieves, AP Duker, RA Hauser, et al. 2017. “Conversion to Carbidopa and Levodopa Extended-Release (IPX066) Followed by Its Extended Use in Patients Previously Taking Controlled-Release Carbidopa-Levodopa for Advanced Parkinson’s Disease. J Neurol Sci 2017;373:116-123.”. J Neurol Sci.